3,434 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Houlihan Financial Resource Group Ltd.

Houlihan Financial Resource Group Ltd. purchased a new stake in Amgen Inc. (NASDAQ:AMGNFree Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,434 shares of the medical research company’s stock, valued at approximately $902,000.

Other institutional investors have also added to or reduced their stakes in the company. OFI Invest Asset Management bought a new stake in shares of Amgen during the 3rd quarter valued at $26,000. Briaud Financial Planning Inc bought a new stake in shares of Amgen during the 3rd quarter valued at $26,000. IAG Wealth Partners LLC lifted its position in shares of Amgen by 520.0% during the 2nd quarter. IAG Wealth Partners LLC now owns 124 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 104 shares during the period. VisionPoint Advisory Group LLC bought a new stake in shares of Amgen during the 2nd quarter valued at $28,000. Finally, Strategic Investment Solutions Inc. IL acquired a new position in shares of Amgen during the 1st quarter worth $28,000. 74.44% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on AMGN shares. Morgan Stanley lowered their price target on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. Truist Financial restated a “buy” rating and issued a $320.00 price target on shares of Amgen in a research report on Wednesday, November 29th. BMO Capital Markets upgraded shares of Amgen from a “market perform” rating to an “outperform” rating and upped their price target for the company from $286.00 to $326.00 in a research report on Tuesday, December 19th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $270.00 price target on shares of Amgen in a research report on Friday, October 20th. Finally, The Goldman Sachs Group upped their price target on shares of Amgen from $313.00 to $350.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $295.30.

Read Our Latest Research Report on Amgen

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 2,096 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $273.03, for a total transaction of $572,270.88. Following the completion of the transaction, the senior vice president now directly owns 10,874 shares of the company’s stock, valued at $2,968,928.22. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.57% of the stock is owned by corporate insiders.

Amgen Stock Down 0.2 %

AMGN traded down $0.65 during midday trading on Monday, reaching $290.47. 780,309 shares of the company were exchanged, compared to its average volume of 2,950,757. The company has a market cap of $155.45 billion, a price-to-earnings ratio of 23.42, a price-to-earnings-growth ratio of 2.74 and a beta of 0.62. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The company’s fifty day moving average price is $295.30 and its 200 day moving average price is $274.74. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72.

Amgen (NASDAQ:AMGNGet Free Report) last released its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion during the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. Amgen’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the company posted $4.09 earnings per share. As a group, analysts expect that Amgen Inc. will post 19.54 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 7th. Stockholders of record on Friday, February 16th will be issued a $2.25 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This is a positive change from Amgen’s previous quarterly dividend of $2.13. This represents a $9.00 annualized dividend and a dividend yield of 3.10%. Amgen’s dividend payout ratio is currently 68.21%.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.